← 返回

CAR-T 细胞治疗(CAR-T)细胞免疫治疗的影响因素与解决策略

英文原题:Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.

查看英文原题

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.

PubMed 2024/08/23(内容时间) Oncol Res Q2 · IF 4.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CAR-T 细胞疗法(CAR-T)在临床应用中取得了突破性进展,开创了创新性癌症治疗的新时代。然而,实施这种新型靶向细胞疗法所面临的挑战日益显著。特别是在实体瘤的临床管理中,肿瘤微环境的免疫抑制效应、CAR-T 细胞局部肿瘤浸润能力有限、肿瘤靶向抗原的异质性、CAR-T 质量、管控及临床不良反应的不确定性等障碍,导致了肿瘤治疗中耐药性增加和依从性下降。这些因素显著阻碍了该治疗方法的广泛采用和应用。本文全面分析了近期关于CAR-T 疗法的临床前和临床报告,同时总结了影响其疗效的关键因素。此外,我们旨在识别现有的解决策略并探讨其当前研究现状。通过这篇综述文章,我们的目标是拓宽进一步探索CAR-T 治疗策略及其临床应用的前景。

展开英文摘要原文

Chimeric antigen receptor T-cesll therapy (CAR-T) has achieved groundbreaking advancements in clinical application, ushering in a new era for innovative cancer treatment.

However, the challenges associated with implementing this novel targeted cell therapy are increasingly significant. Particularly in the clinical management of solid tumors, obstacles such as the immunosuppressive effects of the tumor microenvironment, limited local tumor infiltration capability of CAR-T cells, heterogeneity of tumor targeting antigens, uncertainties surrounding CAR-T quality, control, and clinical adverse reactions have contributed to increased drug resistance and decreased compliance in tumor therapy.

These factors have significantly impeded the widespread adoption and utilization of this therapeutic approach. In this paper, we comprehensively analyze recent preclinical and clinical reports on CAR-T therapy while summarizing crucial factors influencing its efficacy.

Furthermore, we aim to identify existing solution strategies and explore their current research status. Through this review article, our objective is to broaden perspectives for further exploration into CAR-T therapy strategies and their clinical applications.

论文信息

作者
Wang Z、Zhou L、Wu X
第一作者单位
Department of Institute of Laboratory Animal Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.China
通讯作者单位
Ministry of Education and Training, Chengdu Second People's Hospital, Chengdu, China.China
文献类型
综述
期刊
Oncology research2024
原文标识
PubMed 39220130 · DOI 10.32604/or.2024.048564